3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
4
Carcinoma, Renal Cell
3
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Melanoma
1
Kidney Neoplasms
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
18
Nivolumab
6
Radiotherapy
5
Paclitaxel
5
Trastuzumab
4
Specimen Handling
4
Ipilimumab
4
tisotumab vedotin
3
temsirolimus
3
olaparib
3
lenvatinib
3
X-Rays
3
Taxes
3
Surveys and Questionnaires
3
Early Intervention, Educational
3
Cyclophosphamide
3
Carboplatin
3
Biopsy
3
spartalizumab
2
sargramostim
2
rucaparib
2
palbociclib
2
fludarabine
2
epacadostat
2
enzalutamide
2
durvalumab
2
cabozantinib
2
atezolizumab
2
aflibercept
2
Vinorelbine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Colony-Stimulating Factors
×
Genitourinary
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled